| Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
| Hydrogen Sulfide | 15 | 2023 | 39 | 4.820 | Why? | 
| Iris | 20 | 2010 | 26 | 3.000 | Why? | 
| Retina | 18 | 2018 | 280 | 2.880 | Why? | 
| Ciliary Body | 14 | 2018 | 23 | 2.060 | Why? | 
| Cattle | 36 | 2021 | 477 | 1.820 | Why? | 
| Norepinephrine | 19 | 2015 | 110 | 1.690 | Why? | 
| D-Aspartic Acid | 7 | 2018 | 9 | 1.450 | Why? | 
| Hydrogen Peroxide | 12 | 2021 | 190 | 1.430 | Why? | 
| Sympathetic Nervous System | 10 | 2015 | 74 | 1.310 | Why? | 
| Eye | 7 | 2011 | 71 | 1.280 | Why? | 
| Cyclic AMP | 9 | 2012 | 131 | 1.270 | Why? | 
| Ciliary Arteries | 3 | 2018 | 6 | 1.140 | Why? | 
| Intraocular Pressure | 6 | 2018 | 112 | 1.100 | Why? | 
| Ophthalmic Solutions | 4 | 2018 | 18 | 1.080 | Why? | 
| Isoprostanes | 6 | 2014 | 14 | 1.060 | Why? | 
| Animals | 72 | 2023 | 15081 | 1.050 | Why? | 
| Cysteine | 8 | 2019 | 98 | 1.040 | Why? | 
| Aspartic Acid | 6 | 2018 | 47 | 1.030 | Why? | 
| Synaptic Transmission | 9 | 2015 | 146 | 0.960 | Why? | 
| Muscle Contraction | 5 | 2018 | 66 | 0.930 | Why? | 
| Neurotransmitter Agents | 4 | 2011 | 63 | 0.830 | Why? | 
| Serotonin Antagonists | 5 | 2018 | 23 | 0.830 | Why? | 
| Citrates | 8 | 2009 | 14 | 0.820 | Why? | 
| Aqueous Humor | 2 | 2017 | 18 | 0.760 | Why? | 
| Prostaglandins | 8 | 2015 | 27 | 0.720 | Why? | 
| Dose-Response Relationship, Drug | 17 | 2018 | 1039 | 0.710 | Why? | 
| Organothiophosphorus Compounds | 4 | 2018 | 7 | 0.680 | Why? | 
| Tritium | 10 | 2011 | 51 | 0.670 | Why? | 
| Morpholines | 4 | 2018 | 69 | 0.660 | Why? | 
| Peroxides | 4 | 2005 | 20 | 0.630 | Why? | 
| Receptor, Serotonin, 5-HT2C | 1 | 2018 | 5 | 0.630 | Why? | 
| Receptor, Serotonin, 5-HT2B | 1 | 2018 | 6 | 0.630 | Why? | 
| Glaucoma | 2 | 2017 | 85 | 0.600 | Why? | 
| Cyclooxygenase Inhibitors | 9 | 2012 | 30 | 0.600 | Why? | 
| Cystathionine gamma-Lyase | 6 | 2015 | 12 | 0.590 | Why? | 
| Phenylephrine | 2 | 2015 | 36 | 0.590 | Why? | 
| Sulfides | 7 | 2023 | 62 | 0.580 | Why? | 
| Eye Diseases | 3 | 2018 | 24 | 0.570 | Why? | 
| Dinoprost | 5 | 2008 | 22 | 0.560 | Why? | 
| Piperidines | 3 | 2015 | 77 | 0.560 | Why? | 
| Dinoprostone | 7 | 2009 | 63 | 0.560 | Why? | 
| Muscle, Smooth | 4 | 2010 | 58 | 0.550 | Why? | 
| Muscle Relaxation | 4 | 2015 | 19 | 0.530 | Why? | 
| Cystathionine beta-Synthase | 5 | 2015 | 12 | 0.510 | Why? | 
| Pyrrolidines | 1 | 2015 | 29 | 0.510 | Why? | 
| Organophosphorus Compounds | 1 | 2015 | 37 | 0.500 | Why? | 
| Glycine | 4 | 2012 | 47 | 0.500 | Why? | 
| Electric Stimulation | 15 | 2015 | 184 | 0.480 | Why? | 
| Vasoconstrictor Agents | 4 | 2015 | 41 | 0.470 | Why? | 
| Muscle, Smooth, Vascular | 1 | 2015 | 130 | 0.470 | Why? | 
| Potassium Chloride | 5 | 2009 | 28 | 0.470 | Why? | 
| Vasodilation | 1 | 2013 | 65 | 0.450 | Why? | 
| Swine | 6 | 2023 | 184 | 0.420 | Why? | 
| Flurbiprofen | 8 | 2009 | 10 | 0.420 | Why? | 
| KATP Channels | 4 | 2015 | 11 | 0.410 | Why? | 
| Retinal Pigment Epithelium | 1 | 2012 | 30 | 0.400 | Why? | 
| Oxidative Stress | 8 | 2021 | 938 | 0.400 | Why? | 
| Calcium | 3 | 2018 | 480 | 0.380 | Why? | 
| Cataract | 2 | 2021 | 26 | 0.370 | Why? | 
| Catecholamines | 2 | 2018 | 44 | 0.360 | Why? | 
| F2-Isoprostanes | 3 | 2011 | 20 | 0.350 | Why? | 
| Rabbits | 12 | 2016 | 283 | 0.340 | Why? | 
| Serotonin | 4 | 2002 | 123 | 0.330 | Why? | 
| Muscarinic Antagonists | 1 | 2008 | 12 | 0.330 | Why? | 
| Uterus | 4 | 1991 | 55 | 0.330 | Why? | 
| Air Pollutants | 1 | 2009 | 94 | 0.320 | Why? | 
| Glutamic Acid | 3 | 2009 | 128 | 0.300 | Why? | 
| Histamine | 2 | 2006 | 18 | 0.300 | Why? | 
| Catalase | 2 | 2000 | 109 | 0.300 | Why? | 
| Calcium Channel Blockers | 3 | 2003 | 56 | 0.300 | Why? | 
| Free Radicals | 2 | 2005 | 74 | 0.290 | Why? | 
| Carbachol | 5 | 2010 | 19 | 0.290 | Why? | 
| Aporphines | 2 | 2005 | 16 | 0.290 | Why? | 
| Uvea | 2 | 2015 | 3 | 0.290 | Why? | 
| Plant Extracts | 5 | 2004 | 286 | 0.280 | Why? | 
| Appetite Depressants | 2 | 2004 | 9 | 0.280 | Why? | 
| Prostaglandin-Endoperoxide Synthases | 2 | 2000 | 41 | 0.270 | Why? | 
| Ischemia | 1 | 2006 | 46 | 0.270 | Why? | 
| Cannabinoids | 1 | 2006 | 56 | 0.270 | Why? | 
| Rats | 15 | 2012 | 3483 | 0.260 | Why? | 
| Arachidonic Acid | 1 | 2005 | 35 | 0.250 | Why? | 
| Excitatory Amino Acid Agonists | 2 | 2001 | 48 | 0.250 | Why? | 
| Receptors, Prostaglandin | 4 | 2009 | 10 | 0.250 | Why? | 
| Receptors, Serotonin | 4 | 2018 | 22 | 0.240 | Why? | 
| Receptors, Thromboxane | 4 | 2008 | 4 | 0.240 | Why? | 
| Lutein | 1 | 2024 | 5 | 0.240 | Why? | 
| Arachidonic Acids | 1 | 2004 | 24 | 0.240 | Why? | 
| Vitreous Body | 1 | 2003 | 11 | 0.230 | Why? | 
| Alanine | 1 | 2003 | 30 | 0.230 | Why? | 
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2001 | 11 | 0.230 | Why? | 
| Lipid Peroxidation | 3 | 2004 | 140 | 0.230 | Why? | 
| Adrenergic alpha-Agonists | 2 | 1997 | 34 | 0.230 | Why? | 
| Body Weight | 5 | 2007 | 434 | 0.220 | Why? | 
| Isometric Contraction | 2 | 2015 | 23 | 0.220 | Why? | 
| Amino Acids | 1 | 2003 | 145 | 0.220 | Why? | 
| Cerebral Cortex | 2 | 2002 | 290 | 0.210 | Why? | 
| Neurons | 1 | 2009 | 1175 | 0.210 | Why? | 
| Glucose | 1 | 2003 | 230 | 0.210 | Why? | 
| Receptors, Neurotransmitter | 1 | 2001 | 21 | 0.200 | Why? | 
| Excitatory Amino Acid Antagonists | 1 | 2001 | 99 | 0.200 | Why? | 
| Receptors, Muscarinic | 3 | 2010 | 18 | 0.200 | Why? | 
| Organ Culture Techniques | 3 | 2008 | 103 | 0.200 | Why? | 
| Garcinia cambogia | 4 | 2004 | 4 | 0.190 | Why? | 
| Uterine Contraction | 3 | 1991 | 6 | 0.190 | Why? | 
| Alkynes | 2 | 2012 | 50 | 0.190 | Why? | 
| Hydrazines | 4 | 2009 | 21 | 0.180 | Why? | 
| Fatty Acids, Unsaturated | 4 | 2009 | 34 | 0.180 | Why? | 
| Drug Synergism | 4 | 2003 | 177 | 0.180 | Why? | 
| Nitric Oxide | 2 | 2015 | 316 | 0.180 | Why? | 
| Prostaglandins F, Synthetic | 2 | 2016 | 6 | 0.170 | Why? | 
| Thioctic Acid | 2 | 2016 | 14 | 0.170 | Why? | 
| Lens, Crystalline | 1 | 2019 | 13 | 0.170 | Why? | 
| Enzyme Inhibitors | 3 | 2015 | 433 | 0.170 | Why? | 
| Intracellular Fluid | 1 | 1998 | 26 | 0.170 | Why? | 
| Humans | 23 | 2024 | 37093 | 0.160 | Why? | 
| Chromaffin Cells | 1 | 2018 | 4 | 0.160 | Why? | 
| Ophthalmic Artery | 1 | 2018 | 3 | 0.160 | Why? | 
| Exocytosis | 1 | 2018 | 47 | 0.160 | Why? | 
| Excitatory Amino Acids | 1 | 2017 | 7 | 0.160 | Why? | 
| Anterior Eye Segment | 1 | 2017 | 8 | 0.150 | Why? | 
| Anti-Obesity Agents | 2 | 2009 | 10 | 0.150 | Why? | 
| Cells, Cultured | 4 | 2018 | 1518 | 0.140 | Why? | 
| Reactive Oxygen Species | 3 | 2002 | 461 | 0.140 | Why? | 
| Xanthones | 2 | 2009 | 2 | 0.140 | Why? | 
| Cholinergic Agonists | 2 | 2010 | 7 | 0.140 | Why? | 
| Phosphodiesterase Inhibitors | 3 | 2009 | 34 | 0.130 | Why? | 
| Potassium | 3 | 2018 | 112 | 0.130 | Why? | 
| Dopamine | 2 | 1995 | 245 | 0.130 | Why? | 
| Neuropeptide Y | 2 | 1999 | 24 | 0.130 | Why? | 
| 3',5'-Cyclic-AMP Phosphodiesterases | 2 | 2009 | 6 | 0.130 | Why? | 
| Software Design | 1 | 2015 | 16 | 0.130 | Why? | 
| Liver | 3 | 2009 | 479 | 0.130 | Why? | 
| Neuroprotective Agents | 1 | 2017 | 245 | 0.130 | Why? | 
| Albuterol | 3 | 1991 | 9 | 0.120 | Why? | 
| Receptors, Angiotensin | 2 | 1993 | 12 | 0.120 | Why? | 
| Rod Cell Outer Segment | 1 | 1994 | 8 | 0.120 | Why? | 
| Male | 19 | 2016 | 20025 | 0.120 | Why? | 
| Antioxidants | 3 | 2024 | 416 | 0.120 | Why? | 
| Second Messenger Systems | 1 | 1993 | 14 | 0.120 | Why? | 
| DNA Fragmentation | 2 | 2004 | 92 | 0.120 | Why? | 
| Receptors, Prostaglandin E | 2 | 2008 | 3 | 0.120 | Why? | 
| Delayed-Action Preparations | 1 | 2013 | 60 | 0.110 | Why? | 
| Female | 18 | 2004 | 20969 | 0.110 | Why? | 
| Angiotensin II | 1 | 1993 | 97 | 0.110 | Why? | 
| Esophagus | 2 | 1992 | 42 | 0.110 | Why? | 
| Receptors, Adrenergic, alpha-2 | 2 | 2006 | 39 | 0.110 | Why? | 
| Aminooxyacetic Acid | 1 | 2012 | 3 | 0.110 | Why? | 
| Estrus | 2 | 1989 | 14 | 0.100 | Why? | 
| Chromatography, High Pressure Liquid | 2 | 2023 | 421 | 0.100 | Why? | 
| Perfusion | 2 | 2003 | 33 | 0.100 | Why? | 
| Nitrendipine | 2 | 2003 | 2 | 0.100 | Why? | 
| Glutathione | 3 | 2021 | 179 | 0.100 | Why? | 
| Plants, Medicinal | 2 | 2002 | 68 | 0.100 | Why? | 
| Aged | 7 | 2001 | 6741 | 0.100 | Why? | 
| Sympathomimetics | 1 | 1991 | 8 | 0.100 | Why? | 
| Pregnancy, Animal | 1 | 1991 | 16 | 0.100 | Why? | 
| Benzeneacetamides | 1 | 1990 | 6 | 0.100 | Why? | 
| Enzyme Activation | 1 | 2012 | 444 | 0.090 | Why? | 
| Weight Loss | 2 | 2009 | 131 | 0.090 | Why? | 
| Adult | 10 | 2001 | 11712 | 0.090 | Why? | 
| Glyburide | 1 | 2010 | 8 | 0.090 | Why? | 
| 1-Methyl-3-isobutylxanthine | 1 | 2009 | 13 | 0.090 | Why? | 
| Dietary Supplements | 2 | 2009 | 208 | 0.090 | Why? | 
| Superoxide Dismutase | 2 | 2021 | 155 | 0.090 | Why? | 
| Hydrogen | 2 | 2021 | 47 | 0.090 | Why? | 
| Glutamine | 1 | 2009 | 40 | 0.090 | Why? | 
| Rats, Sprague-Dawley | 5 | 2004 | 1618 | 0.090 | Why? | 
| Middle Aged | 8 | 2001 | 10129 | 0.090 | Why? | 
| Aging | 1 | 1994 | 664 | 0.090 | Why? | 
| Rats, Inbred Strains | 4 | 1991 | 133 | 0.080 | Why? | 
| Naloxone | 1 | 1989 | 52 | 0.080 | Why? | 
| Narcotics | 1 | 1989 | 32 | 0.080 | Why? | 
| Miotics | 1 | 2008 | 2 | 0.080 | Why? | 
| Sus scrofa | 1 | 2008 | 19 | 0.080 | Why? | 
| Adrenergic beta-Agonists | 1 | 1988 | 28 | 0.080 | Why? | 
| Melatonin | 3 | 2002 | 82 | 0.080 | Why? | 
| Obesity | 2 | 2007 | 1067 | 0.070 | Why? | 
| Biguanides | 2 | 2003 | 7 | 0.070 | Why? | 
| Histamine Agonists | 1 | 2006 | 1 | 0.070 | Why? | 
| Receptors, Histamine | 1 | 2006 | 3 | 0.070 | Why? | 
| Histamine Antagonists | 1 | 2006 | 6 | 0.070 | Why? | 
| Administration, Oral | 2 | 2004 | 224 | 0.070 | Why? | 
| Lipids | 2 | 2004 | 235 | 0.070 | Why? | 
| Ocular Hypotension | 1 | 2005 | 3 | 0.060 | Why? | 
| Insulin Resistance | 1 | 2007 | 184 | 0.060 | Why? | 
| Yohimbine | 2 | 1998 | 26 | 0.060 | Why? | 
| Food Additives | 1 | 2004 | 3 | 0.060 | Why? | 
| Calcium Channels | 2 | 2018 | 76 | 0.060 | Why? | 
| Clonidine | 2 | 1998 | 52 | 0.060 | Why? | 
| Mitochondria | 2 | 2018 | 487 | 0.060 | Why? | 
| Diltiazem | 1 | 2003 | 5 | 0.060 | Why? | 
| Verapamil | 1 | 2003 | 7 | 0.060 | Why? | 
| omega-Conotoxins | 1 | 2003 | 4 | 0.060 | Why? | 
| Kainic Acid | 1 | 2003 | 48 | 0.060 | Why? | 
| Receptors, Glutamate | 1 | 2003 | 27 | 0.060 | Why? | 
| Dizocilpine Maleate | 1 | 2003 | 48 | 0.060 | Why? | 
| Macular Degeneration | 1 | 2024 | 29 | 0.060 | Why? | 
| N-Methylaspartate | 1 | 2003 | 57 | 0.060 | Why? | 
| Polyamines | 1 | 2003 | 30 | 0.060 | Why? | 
| Phytotherapy | 1 | 2004 | 81 | 0.060 | Why? | 
| Cyclic GMP | 2 | 1993 | 47 | 0.060 | Why? | 
| Chromatography, Liquid | 1 | 2023 | 142 | 0.050 | Why? | 
| Tryptamines | 1 | 2002 | 7 | 0.050 | Why? | 
| Dermis | 1 | 2002 | 8 | 0.050 | Why? | 
| Naphthalenes | 1 | 2002 | 38 | 0.050 | Why? | 
| Appetite | 1 | 2002 | 21 | 0.050 | Why? | 
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 448 | 0.050 | Why? | 
| Administration, Cutaneous | 1 | 2002 | 43 | 0.050 | Why? | 
| Testis | 1 | 2003 | 187 | 0.050 | Why? | 
| Hypersensitivity, Immediate | 2 | 2000 | 11 | 0.050 | Why? | 
| Inflammation | 1 | 2007 | 618 | 0.050 | Why? | 
| Vitamin E | 1 | 2002 | 61 | 0.050 | Why? | 
| Tandem Mass Spectrometry | 1 | 2023 | 182 | 0.050 | Why? | 
| Thromboxane-A Synthase | 1 | 2001 | 1 | 0.050 | Why? | 
| Isomerism | 1 | 2001 | 63 | 0.050 | Why? | 
| Peptides | 2 | 1998 | 320 | 0.050 | Why? | 
| Isoquinolines | 1 | 2001 | 45 | 0.050 | Why? | 
| Osmolar Concentration | 1 | 2001 | 58 | 0.050 | Why? | 
| Disease Models, Animal | 1 | 2006 | 1371 | 0.050 | Why? | 
| Amitrole | 1 | 2000 | 4 | 0.050 | Why? | 
| Benzene Derivatives | 1 | 2000 | 4 | 0.050 | Why? | 
| Reproducibility of Results | 1 | 2023 | 935 | 0.050 | Why? | 
| Prostaglandins E | 2 | 1991 | 3 | 0.050 | Why? | 
| Beclomethasone | 1 | 2000 | 2 | 0.050 | Why? | 
| Receptors, Metabotropic Glutamate | 1 | 2000 | 28 | 0.050 | Why? | 
| Oxidants | 1 | 2000 | 45 | 0.050 | Why? | 
| Phosphoric Diester Hydrolases | 1 | 2000 | 19 | 0.050 | Why? | 
| Anti-Asthmatic Agents | 1 | 2000 | 31 | 0.040 | Why? | 
| Reference Standards | 1 | 2019 | 52 | 0.040 | Why? | 
| Acetylcholine | 2 | 1991 | 73 | 0.040 | Why? | 
| Ganglionectomy | 1 | 1999 | 2 | 0.040 | Why? | 
| Ruthenium Red | 1 | 1998 | 4 | 0.040 | Why? | 
| Thapsigargin | 1 | 1998 | 7 | 0.040 | Why? | 
| Oligomycins | 1 | 1998 | 4 | 0.040 | Why? | 
| Calcium-Transporting ATPases | 1 | 1998 | 16 | 0.040 | Why? | 
| Egtazic Acid | 1 | 1998 | 13 | 0.040 | Why? | 
| Neuroeffector Junction | 1 | 1998 | 1 | 0.040 | Why? | 
| Oxymetazoline | 1 | 1998 | 3 | 0.040 | Why? | 
| Adrenergic Fibers | 1 | 1998 | 3 | 0.040 | Why? | 
| Culture Techniques | 1 | 1998 | 24 | 0.040 | Why? | 
| Quinoxalines | 1 | 1998 | 27 | 0.040 | Why? | 
| Chelating Agents | 1 | 1998 | 57 | 0.040 | Why? | 
| omega-Conotoxin GVIA | 1 | 1998 | 6 | 0.040 | Why? | 
| Feeding Behavior | 1 | 2002 | 454 | 0.040 | Why? | 
| Cytosol | 1 | 2018 | 93 | 0.040 | Why? | 
| Blood Flow Velocity | 1 | 2018 | 61 | 0.040 | Why? | 
| Retinal Diseases | 1 | 2017 | 17 | 0.040 | Why? | 
| CD4-Positive T-Lymphocytes | 1 | 2000 | 259 | 0.040 | Why? | 
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1997 | 1 | 0.040 | Why? | 
| Endoplasmic Reticulum | 1 | 2018 | 105 | 0.040 | Why? | 
| Calcium Signaling | 1 | 2018 | 101 | 0.040 | Why? | 
| Homeostasis | 1 | 1998 | 188 | 0.040 | Why? | 
| Free Radical Scavengers | 1 | 1997 | 66 | 0.040 | Why? | 
| Rats, Inbred F344 | 1 | 1997 | 245 | 0.040 | Why? | 
| Sulfonamides | 2 | 2009 | 80 | 0.030 | Why? | 
| Drug Delivery Systems | 1 | 2018 | 202 | 0.030 | Why? | 
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1995 | 15 | 0.030 | Why? | 
| Cytokines | 1 | 1998 | 602 | 0.030 | Why? | 
| Thiobarbituric Acid Reactive Substances | 1 | 1994 | 15 | 0.030 | Why? | 
| Membrane Fluidity | 1 | 1994 | 11 | 0.030 | Why? | 
| Luminescent Measurements | 1 | 1994 | 26 | 0.030 | Why? | 
| Prostaglandin Antagonists | 1 | 1994 | 1 | 0.030 | Why? | 
| Xanthenes | 1 | 1994 | 11 | 0.030 | Why? | 
| Apomorphine | 1 | 1994 | 13 | 0.030 | Why? | 
| Receptors, Melatonin | 1 | 1994 | 12 | 0.030 | Why? | 
| Saralasin | 1 | 1993 | 1 | 0.030 | Why? | 
| Blood Pressure | 1 | 2018 | 646 | 0.030 | Why? | 
| Stimulation, Chemical | 1 | 1993 | 22 | 0.030 | Why? | 
| Phosphatidylinositols | 1 | 1993 | 12 | 0.030 | Why? | 
| Receptors, Dopamine D2 | 1 | 1994 | 73 | 0.030 | Why? | 
| Receptors, Cell Surface | 1 | 1994 | 144 | 0.030 | Why? | 
| Cell Membrane | 1 | 1994 | 381 | 0.030 | Why? | 
| Prostaglandins E, Synthetic | 1 | 1991 | 1 | 0.030 | Why? | 
| Adolescent | 3 | 1998 | 5363 | 0.020 | Why? | 
| Sodium Channels | 1 | 1991 | 67 | 0.020 | Why? | 
| Epinephrine | 1 | 1991 | 36 | 0.020 | Why? | 
| Receptors, Adrenergic, alpha | 1 | 1990 | 18 | 0.020 | Why? | 
| Indomethacin | 1 | 1990 | 28 | 0.020 | Why? | 
| Hydroxamic Acids | 1 | 1990 | 32 | 0.020 | Why? | 
| Pancreatic Polypeptide | 1 | 1990 | 2 | 0.020 | Why? | 
| Peptide YY | 1 | 1990 | 2 | 0.020 | Why? | 
| Atropine | 1 | 1990 | 13 | 0.020 | Why? | 
| Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide | 1 | 2009 | 1 | 0.020 | Why? | 
| Endometrium | 1 | 1991 | 60 | 0.020 | Why? | 
| Nitrobenzenes | 1 | 2009 | 19 | 0.020 | Why? | 
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 5 | 0.020 | Why? | 
| Benzofurans | 1 | 2009 | 21 | 0.020 | Why? | 
| Biphenyl Compounds | 1 | 2009 | 53 | 0.020 | Why? | 
| Phytohemagglutinins | 2 | 2000 | 13 | 0.020 | Why? | 
| Drug Interactions | 1 | 1990 | 141 | 0.020 | Why? | 
| Enkephalin, Methionine | 1 | 1989 | 7 | 0.020 | Why? | 
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1989 | 17 | 0.020 | Why? | 
| Enkephalins | 1 | 1989 | 33 | 0.020 | Why? | 
| Time Factors | 2 | 2004 | 1742 | 0.020 | Why? | 
| Aged, 80 and over | 2 | 1993 | 2379 | 0.020 | Why? | 
| Benzopyrans | 1 | 1988 | 14 | 0.020 | Why? | 
| Guanidines | 1 | 1988 | 17 | 0.020 | Why? | 
| Morphine | 1 | 1989 | 85 | 0.020 | Why? | 
| Pyrroles | 1 | 1988 | 55 | 0.020 | Why? | 
| Papaverine | 1 | 1988 | 2 | 0.020 | Why? | 
| Lipoxygenase Inhibitors | 1 | 1988 | 6 | 0.020 | Why? | 
| Clinical Trials as Topic | 1 | 2009 | 204 | 0.020 | Why? | 
| Ovariectomy | 1 | 1988 | 105 | 0.020 | Why? | 
| Rats, Zucker | 1 | 2007 | 23 | 0.020 | Why? | 
| Drug Evaluation, Preclinical | 1 | 2007 | 112 | 0.020 | Why? | 
| Triglycerides | 1 | 2007 | 138 | 0.020 | Why? | 
| Eating | 1 | 2007 | 166 | 0.020 | Why? | 
| Antihypertensive Agents | 1 | 1988 | 284 | 0.020 | Why? | 
| Pregnancy | 1 | 1991 | 1549 | 0.020 | Why? | 
| Disease Progression | 1 | 2007 | 601 | 0.020 | Why? | 
| Signal Transduction | 1 | 1993 | 1908 | 0.020 | Why? | 
| Hematologic Tests | 1 | 2004 | 7 | 0.020 | Why? | 
| Toxicity Tests | 1 | 2004 | 43 | 0.020 | Why? | 
| Brain Diseases | 1 | 2004 | 32 | 0.010 | Why? | 
| ATP Citrate (pro-S)-Lyase | 1 | 2003 | 2 | 0.010 | Why? | 
| Blood Proteins | 1 | 2004 | 66 | 0.010 | Why? | 
| Organ Size | 1 | 2004 | 157 | 0.010 | Why? | 
| Lung Diseases | 1 | 2004 | 61 | 0.010 | Why? | 
| Heart Diseases | 1 | 2004 | 104 | 0.010 | Why? | 
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2002 | 6 | 0.010 | Why? | 
| Tropanes | 1 | 2002 | 6 | 0.010 | Why? | 
| Receptors, Serotonin, 5-HT3 | 1 | 2002 | 7 | 0.010 | Why? | 
| Inhalation Exposure | 1 | 2002 | 43 | 0.010 | Why? | 
| Prodrugs | 1 | 2002 | 24 | 0.010 | Why? | 
| CHO Cells | 1 | 2002 | 124 | 0.010 | Why? | 
| Randomized Controlled Trials as Topic | 1 | 2004 | 268 | 0.010 | Why? | 
| Tocopherols | 1 | 2002 | 65 | 0.010 | Why? | 
| Leptin | 1 | 2003 | 118 | 0.010 | Why? | 
| Cricetinae | 1 | 2002 | 238 | 0.010 | Why? | 
| Fruit | 1 | 2004 | 173 | 0.010 | Why? | 
| Kidney Diseases | 1 | 2004 | 167 | 0.010 | Why? | 
| Curcumin | 1 | 2002 | 74 | 0.010 | Why? | 
| Risk Assessment | 1 | 2004 | 753 | 0.010 | Why? | 
| Rhinitis, Allergic, Seasonal | 1 | 2000 | 4 | 0.010 | Why? | 
| Th2 Cells | 1 | 2000 | 58 | 0.010 | Why? | 
| Molecular Structure | 1 | 2001 | 492 | 0.010 | Why? | 
| Analysis of Variance | 1 | 2001 | 550 | 0.010 | Why? | 
| Interleukin-2 | 1 | 2000 | 89 | 0.010 | Why? | 
| Body Mass Index | 1 | 2004 | 854 | 0.010 | Why? | 
| Superior Cervical Ganglion | 1 | 1999 | 5 | 0.010 | Why? | 
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 1998 | 9 | 0.010 | Why? | 
| Tetradecanoylphorbol Acetate | 1 | 1998 | 41 | 0.010 | Why? | 
| Lymphocyte Activation | 1 | 2000 | 236 | 0.010 | Why? | 
| Interleukin-10 | 1 | 1998 | 75 | 0.010 | Why? | 
| Glucocorticoids | 1 | 1998 | 86 | 0.010 | Why? | 
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 121 | 0.010 | Why? | 
| Mice, Inbred C57BL | 1 | 2002 | 1609 | 0.010 | Why? | 
| Leukocytes, Mononuclear | 1 | 1998 | 234 | 0.010 | Why? | 
| Tumor Necrosis Factor-alpha | 1 | 1998 | 356 | 0.010 | Why? | 
| Cell Line | 1 | 2000 | 1354 | 0.010 | Why? | 
| Asthma | 1 | 2000 | 380 | 0.010 | Why? | 
| Receptors, Neuropeptide Y | 1 | 1993 | 8 | 0.010 | Why? | 
| Receptors, Adrenergic | 1 | 1993 | 11 | 0.010 | Why? | 
| Mice | 1 | 2002 | 5913 | 0.010 | Why? | 
| Cromakalim | 1 | 1988 | 1 | 0.010 | Why? | 
| Pinacidil | 1 | 1988 | 1 | 0.010 | Why? | 
| Rubidium Radioisotopes | 1 | 1988 | 2 | 0.010 | Why? | 
| Tetrodotoxin | 1 | 1988 | 22 | 0.010 | Why? | 
| Nifedipine | 1 | 1988 | 10 | 0.010 | Why? | 
| Guinea Pigs | 1 | 1988 | 145 | 0.010 | Why? | 
| Potassium Channels | 1 | 1988 | 75 | 0.000 | Why? | 
| Child | 1 | 1993 | 3131 | 0.000 | Why? |